B

BioGeometry

AIDrug DesignB2B📍 Beijing, China

BioGeometry is an AI-native biopharma company that uses generative AI to create "micro-world models" of biology for designing antibodies, vaccines, peptides, and enzymes. They pair these models with automated labs in a dry-wet feedback loop to improve the system over time. This Series A extension will fund model iteration, lab expansion, and advancing their drug pipeline.

Total raised
Undisclosed
tracked to date
Latest round
Series A
Oct 28, 2026
Known investors
6
led by China Life Capital

Is this your company?

Claim this profile to get matched with investors who fund AI startups in China.

Claim this profile →

Funding history

  1. 1
    $100MSeries AOct 28, 2026

    Led by China Life Capital

    Announcement ↗

Investors in BioGeometry

Backers from this company's tracked funding rounds.

  • CChina Life CapitalLead investorVC firm
  • SShanghai Biopharmaceutical FundVC firm
  • CCDB KechuangVC firm
  • FFortune CapitalVC firm
  • GGuofang CapitalVC firm
  • RRuili InvestmentVC firm

BioGeometry in the news

Coverage of this company's funding, tracked by Datapile.

More AI companies

Recently funded startups in the same category.

Related on Datapile